P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES

• Michal Kwiatek,
• Guru Subramanian Guru Murthy,
• Marc Hoffmann,
• Lindsey Roeker,
• Benoit Tessoulin,
• Alexey Danilov,
• Alvaro J. Alencar,
• Nirav N. Shah,
• Herve Ghesquieres,
• Steven Le Gouill,
• Wojciech Jurczak,
• Anthony R. Mato,
• Vishalkumar Patel,
• Yingying Guo-Avrutin,
• James M. Pauff,
• Maciej Kazmierczak

Affiliations

Michal Kwiatek

1 Centrum Medyczne Pratia, Poznan, Poland

Guru Subramanian Guru Murthy

2 Medical College of Wisconsin, Milwaukee, WI, United States

Marc Hoffmann

3 Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Overland Park, KS, United States

Lindsey Roeker

4 Memorial Sloan Kettering Cancer Center,, New York, NY, United States

Benoit Tessoulin

5 Service d’Hématologie Clinique, CHU de Nantes, Place Alexis Ricordeau, 44000 Nantes, France

Alexey Danilov

6 Toni Stephenson Lymphoma Center, City of Hope National Medical Center, Duarte, CA, United States

Alvaro J. Alencar

7 Department of Medicine, Division of Hematology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, United States

Nirav N. Shah

2 Medical College of Wisconsin, Milwaukee, WI, United States

Herve Ghesquieres

8 Département d’hématologie, centre hospitalier Lyon Sud, Pierre-Bénite, France

Steven Le Gouill

9 Institut Curie Hospital, 75248 Paris, France

Wojciech Jurczak

10 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

Anthony R. Mato

4 Memorial Sloan Kettering Cancer Center,, New York, NY, United States

Vishalkumar Patel

11 Loxo@Lilly, Stamford, CT, United States

Yingying Guo-Avrutin

11 Loxo@Lilly, Stamford, CT, United States

James M. Pauff

11 Loxo@Lilly, Stamford, CT, United States

Maciej Kazmierczak

1 Centrum Medyczne Pratia, Poznan, Poland